{
  "ptid_time": "114_S_0378_2006-04-04",
  "img_path": "/data/qiuhui/data/adni/images/114_S_0378/2006-04-04/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 36,353 mm³, 62.7% above the reference mean. With a Z-score of 1.57 (94.2th percentile), this represents moderate enlargement; hippocampal volume measures 6,132 mm³, 20.2% below the reference mean. With a Z-score of -2.27 (1.2th percentile), this represents significant atrophy; whole brain volume measures 920,176 mm³, 10.6% below the reference mean. With a Z-score of -1.32 (9.4th percentile), this represents mild atrophy; entorhinal cortex volume measures 3,294 mm³, 15.4% below the reference mean. With a Z-score of -1.19 (11.7th percentile), this represents mild atrophy; fusiform gyrus volume measures 14,681 mm³, 19.4% below the reference mean. With a Z-score of -2.18 (1.5th percentile), this represents significant atrophy; middle temporal gyrus volume measures 17,825 mm³, 13.1% below the reference mean. With a Z-score of -1.17 (12.2th percentile), this represents mild atrophy. ",
  "text_data": "Age is 69.0 years. Gender is Female. Education: 16 years. Handedness: Right. Race: White. Medical history: Endocrine-Metabolic; Renal-Genitourinary; Allergies or Drug Sensitivities. MMSE: 28.0. Logical Memory: 0.0. APOEε4 alleles: 1.0. Biomarker levels: Amyloid beta: 482.90 pg/mL (mild reduced); Total tau: 521.80 pg/mL (profound elevated); Phosphorylated tau: 56.81 pg/mL (profound elevated). ",
  "true_diagnosis": "Diagnosis: MCI.",
  "gpt_diagnosis": "**Reasoning:** The imaging data shows significant hippocampal and fusiform gyrus atrophy, along with mild-to-moderate atrophy in other regions, consistent with Alzheimer's pathology. Elevated T-tau and P-tau with mildly reduced Aβ further support AD biomarkers, though the high MMSE score (28) suggests preserved cognitive function.  \n**Diagnosis:** **MCI** (likely prodromal Alzheimer's due to biomarker and structural changes, but intact global cognition).  \n**Confidence:** **Medium** (high biomarker/imaging confidence for AD pathology, but clinical symptoms do not yet meet dementia criteria).  \n\n*Note: The discrepancy between structural/biomarker severity and MMSE highlights possible pre-symptomatic or very early symptomatic AD. Follow-up cognitive testing (e.g., episodic memory assessments) would strengthen confidence.*",
  "timestamp": "2025-07-26T11:39:40.311059"
}